CGIM
DNTH icon

Cannon Global Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

Cannon Global Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,100
Closed -$428K – 61
2026
Q1 		$428K Buy
+5,100
New +$295K 0.84% 40

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Cannon Global Investment Management's DNTH Position: Q2 2026 in Review

Cannon Global Investment Management sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 5,100 shares — an estimated $428K sold.

Cannon Global Investment Management first reported a position in DNTH in Q1 2026 and held it in 1 quarter. The position peaked at $428K in Q1 2026. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Cannon Global Investment Management reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cannon Global Investment Management sold 5,100 Dianthus Therapeutics shares in Q2 2026, an estimated $428K.
  • Cannon Global Investment Management first reported a position in Dianthus Therapeutics in Q1 2026 and held it in 1 quarter.
  • Cannon Global Investment Management's Dianthus Therapeutics position peaked at $428K in Q1 2026.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.